基于阿奴韦林/拉米夫定/替诺福韦抗击 HIV-1 的比较研究

IF 1.3 4区医学 Q4 IMMUNOLOGY

International Journal of STD & AIDS Pub Date : 2024-09-14 DOI:10.1177/09564624241282366

Peipei Luo, Juan Jin, Jiajia Li, Jinling Yin, Xinyan Jing, Haohua Hou, Huanhuan Ba, Yuan Zhang

{"title":"基于阿奴韦林/拉米夫定/替诺福韦抗击 HIV-1 的比较研究","authors":"Peipei Luo, Juan Jin, Jiajia Li, Jinling Yin, Xinyan Jing, Haohua Hou, Huanhuan Ba, Yuan Zhang","doi":"10.1177/09564624241282366","DOIUrl":null,"url":null,"abstract":"BackgroundAinuovirine, as a third-generation non-nucleoside reverse transcriptase inhibitor against HIV-1, is widely used in China. To evaluate its therapeutic efficacy and disadvantages, a comparative study based on Ainuovirine had been conducted.MethodWe investigated 199 people living with HIV-1 who received Ainuovirine (ANV)/lamivudine/tenofovir and 202 people living with HIV-1 who received Efavirenz (EFV)/lamivudine/tenofovir.ResultsAfter 48 weeks of therapy, ANV and EFV showed similar viral inhibitory effects. However, in the ANV group, more participants had CD4/CD8 ratios restored to the normal range, lower levels of triglycerides and low-density lipoprotein, relatively normal liver alanine aminotransferase, and fewer adverse events.ConclusionTherefore, due to its role in immune reconstitution, dyslipidemia, and safety, ANV may be a recommended option for people living with HIV-1.","PeriodicalId":14408,"journal":{"name":"International Journal of STD & AIDS","volume":"42 1","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A comparative study based on ainuovirine/lamivudine/tenofovir against HIV-1\",\"authors\":\"Peipei Luo, Juan Jin, Jiajia Li, Jinling Yin, Xinyan Jing, Haohua Hou, Huanhuan Ba, Yuan Zhang\",\"doi\":\"10.1177/09564624241282366\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BackgroundAinuovirine, as a third-generation non-nucleoside reverse transcriptase inhibitor against HIV-1, is widely used in China. To evaluate its therapeutic efficacy and disadvantages, a comparative study based on Ainuovirine had been conducted.MethodWe investigated 199 people living with HIV-1 who received Ainuovirine (ANV)/lamivudine/tenofovir and 202 people living with HIV-1 who received Efavirenz (EFV)/lamivudine/tenofovir.ResultsAfter 48 weeks of therapy, ANV and EFV showed similar viral inhibitory effects. However, in the ANV group, more participants had CD4/CD8 ratios restored to the normal range, lower levels of triglycerides and low-density lipoprotein, relatively normal liver alanine aminotransferase, and fewer adverse events.ConclusionTherefore, due to its role in immune reconstitution, dyslipidemia, and safety, ANV may be a recommended option for people living with HIV-1.\",\"PeriodicalId\":14408,\"journal\":{\"name\":\"International Journal of STD & AIDS\",\"volume\":\"42 1\",\"pages\":\"\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2024-09-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of STD & AIDS\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/09564624241282366\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of STD & AIDS","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/09564624241282366","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景阿奴韦林作为第三代非核苷类逆转录酶抑制剂，在中国被广泛使用。结果治疗48周后，ANV和EFV显示出相似的病毒抑制效果。然而，在ANV组中，更多参与者的CD4/CD8比率恢复到了正常范围，甘油三酯和低密度脂蛋白水平较低，肝脏丙氨酸氨基转移酶相对正常，不良反应较少。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A comparative study based on ainuovirine/lamivudine/tenofovir against HIV-1

BackgroundAinuovirine, as a third-generation non-nucleoside reverse transcriptase inhibitor against HIV-1, is widely used in China. To evaluate its therapeutic efficacy and disadvantages, a comparative study based on Ainuovirine had been conducted.MethodWe investigated 199 people living with HIV-1 who received Ainuovirine (ANV)/lamivudine/tenofovir and 202 people living with HIV-1 who received Efavirenz (EFV)/lamivudine/tenofovir.ResultsAfter 48 weeks of therapy, ANV and EFV showed similar viral inhibitory effects. However, in the ANV group, more participants had CD4/CD8 ratios restored to the normal range, lower levels of triglycerides and low-density lipoprotein, relatively normal liver alanine aminotransferase, and fewer adverse events.ConclusionTherefore, due to its role in immune reconstitution, dyslipidemia, and safety, ANV may be a recommended option for people living with HIV-1.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of STD & AIDS 医学-传染病学

CiteScore

2.60

自引率

7.10%

发文量

144

审稿时长

3-6 weeks

期刊介绍： The International Journal of STD & AIDS provides a clinically oriented forum for investigating and treating sexually transmissible infections, HIV and AIDS. Publishing original research and practical papers, the journal contains in-depth review articles, short papers, case reports, audit reports, CPD papers and a lively correspondence column. This journal is a member of the Committee on Publication Ethics (COPE).